- Remove All
Your shopping cart is currently empty
Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties. Upon ophthalmic administration, bromfenac binds to and inhibits cyclooxygenase II (COX II), an enzyme that converts arachidonic acid to cyclic endoperoxides, which are prostaglandin (PG) precursors. By inhibiting PG formation, bromfenac prevents PG-induced inflammation, vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, increased vascular permeability, and elevated intraocular pressure (IOP).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $30 | In Stock | |
| 25 mg | $38 | In Stock | |
| 50 mg | $48 | In Stock | |
| 100 mg | $74 | In Stock | |
| 500 mg | $178 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $30 | In Stock |
| Description | Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties. Upon ophthalmic administration, bromfenac binds to and inhibits cyclooxygenase II (COX II), an enzyme that converts arachidonic acid to cyclic endoperoxides, which are prostaglandin (PG) precursors. By inhibiting PG formation, bromfenac prevents PG-induced inflammation, vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, increased vascular permeability, and elevated intraocular pressure (IOP). |
| Targets&IC50 | COX-1:5.56 nM (IC50), COX-2:7.45 nM (IC50) |
| Synonyms | Bromfenac sodium sesquihydrate, Bromfenac monosodium salt sesquihydrate |
| Molecular Weight | 383.17 |
| Formula | C15H12BrNO3·3/2H2O·Na |
| Cas No. | 120638-55-3 |
| Smiles | O.[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c1ccc(Br)cc1 |
| Relative Density. | 1.565 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 12.5 mg/mL (32.62 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.22 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.